Peter Sklar

机构：Merck & Co., Inc., Rahway, NJ, USA (United States), Gilead Sciences (United States) · ORCID：0009-0000-7071-6942

发表论文 68 篇 · 总被引 3862 次 · h-index 31

代表论文

• Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial (2019 · The Lancet HIV · 被引 98)
• Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial (2019 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 97)
• Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial (2021 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 55)
• Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development (2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 49)
• Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial (2021 · The Lancet HIV · 被引 46)
• Changes in weight and BMI with first-line doravirine-based therapy (2020 · AIDS · 被引 44)